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INTRODUCTION
Thalassaemia Major a hereditary blood 
disease, widespread in the Mediterranean 
countries, Asia and Africa, in which here is an 
abnormality in the protein part of haemoglobin 
molecule. For the successful treatment of 
Thalassaemia, it requires two key elements- Blood 
Transfusion and Iron Chelation. Regular blood 
transfusion considerably expands the life span of 
patients. Due to regular blood transfusions the 
iron accumulates in the body. The cause of death 
of these patients in 2nd and 3rd decades of life is the 
iron overload[1]. For this they have to depend on 
the iron chelating agents to reduce the iron 
overload due to disease or excess blood 
transfusion and also due to excess dietary 
absorption of iron from gut, to compensate the 
large turnover of red cell mass[2]. 
Desferrioxamine is the gold standard in 
the management of iron overload, besides this it 
has not become popular particularly in the 
developing countries and is being used in only 
10% to 15% of thalassaemics in our country. This 
is mainly due to high cost and the need for 
continuous subcutaneous injection over 6 to 8 
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hours(3). Hence, need is felt to formulate a dosage 
form which can reduce iron overload, cost 
effective and convenient to administer. 
Need of the study 
 A major problem encountered in the 
management of Thalassaemia is iron overload. 
 The most common cause of death in 2nd and 
3rd decade of life is iron overload.[1] 
 There are around 65,000- 67,000 
Thalassaemic patients in our country and 
about 1,00,000 children are born worldwide 
with Thalassaemia every year[14]. 
 The cost of iron chelators which are available 
is high and not easy to administer, some of 
them also have some side effects.  
METHODS 
Aims and Objectives 
1. To evaluate the effect of test drug Lohadosh 
Niwaraka Yog in iron overloading of 
Thalassaemic patients. 
Contents of Trial Drug 
The symptoms of iron overload in 
Thalassaemia closely resembles with the 
hazardous effects of improperly incinerated 
Loha.[4,5] While mentioning its treatment Ayurved 
Prakash advocates the use of Agastipatrabhavita 
Vidang with the Anupana of Agastipatraswarasa 
[6,7,8]. Triphala, Trikatu as told in ‘Chakradatta 
Rasayana Chapter under ‘Amritsaar Loha’[9] for 
minimizing the ill effects of iron on body. Mustak 
is also told in treatment of hazardous effects of 
loha[10]. As Yavaksharais dipan, pachan and mutral 
was also added[11]. Kushmanda is mentioned in the 
‘KakarashtakVarga[12] and also in the 
‘Lohasevinam Varjaniyani’[13] whose 
administration has been contra-indicated during 
the lohabhasma consumption and Rasa aushadhi 
consumption. The Kushmanda was given in this 
study with the Lohadosh Niwarak Yog as a Pathya. 
This study was conducted individually though it 
was related with one of the Thesis work. 
Table 1: Contents of Lohadosh Niwaraka Yog 
No. Ayurvedic Name Latin Name Part Used 
1 Haritaki Terminalia chebula Fruit 
2 Bibhitak Terminalia bellirica Fruit 
3 Amalaki Emblicaofficinalis Fruit 
4 Shunthi Zinziberofficinale Ryzome 
5 Marich Piper nigrum Fruit 
6 Pippali Piper longum Fruit 
7 Vidanga Embeliaribes Fruit 
8 Mustak Cyperusrotundus Ryzome 
9 Agasti Sesbania grandiflora Leaves 
10 Yava Hordiumvulgare Kshara 
 Criteria for selection of patients 
1. Patients having the signs and symptoms of 
Thalassaemia were selected irrespective of 
their sex, religion and occupation. 
2. A detailed proforma was prepared and 
detailed history and physical examination was 
carried out. 
3. An informed written consent of the patient 
was taken before the commencement of 
clinical trials.  
4. Lab investigations like CBC and Hb count, LFT, 
RFT and Serum ferritin etc. were carried out 
before & after the study. 
Exclusion Criteria 
1. Patients suffering from cardiac disorders and 
anemia due to any other cause were debarred 
from the present study. 
2. Those patients having complications like 
Hepatitis-B and other viral infections etc were 
also excluded. 
Grouping 
Selected patients were divided into two 
groups randomly with 20 patients in each group. 
The study was conducted at Thalassaemia 
Unit, JK Lon Pediatrics Hospital, S.M.S Medical 
College Jaipur during the period of May 2010 to 
Jan 2011. 
Group A: Trial Drug Lohadosh Niwarak Yog + The 
chelator advised by Thalassaemic Unit (Kelfer) 
Deferiprone. 
Group B: The chelator advised by Thalassaemic 
Unit (Kelfer) Deferiprone. 
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Posology-Dose 
Group A: 3 gm trial drug in suitable dosage form 
will be given + Kelfer 
Group B: Kelfer 
Anupana: Water 
Pathya: Kushmanda will be told to be taken in the 
form of ‘Petha’ as a pathya two pieces daily only in 
group A patients. 
Duration: Twenty one days. 
Follow up: Patients were reviewed after 7 days. 
Criteria for Assessment: Assessment of the 
treatment was done on the basis of. 
1. Relief in subjective and objective signs and 
symptoms and improvement in general health 
of Thalassaemic patients. 
a) Subjective improvement-All the patients 
registered for clinical trial were looked for 
any changes in their clinical manifestations 
and growing feeling of well being.  
b) Objective improvement was evaluated 
through laboratory investigations like CBC, 
Hb count, LFT, RFT and Serum Ferritin etc. 
2. Statistical analysis 
The information gathered on the basis of classical 
symptomatology was subjected to statistical 
analysis in terms of mean (X), standard deviation 
(SD) and standard error (SE). Wilcoxon matched 
paired single ranked test and Student ‘t’ test 
was carried out at P<0.05, P<0.01, P<0.001 
significance level. The obtained results were 
interpreted as. 
Insignificant : P<0.05, P<0.1 
Significant : P<0.01 
Highly Significant : P<0.001 
Scoring pattern 
To evaluate the drug efficacy the following 
scoring pattern was adopted for the present study. 
1. Aruchi (Anorexia) 
Absent : 0 
Taking normal diet, without any 
interest 
: 1 
Taking the food without interest and 
unable to complete it all the time 
: 2 
Not interested in taking food, resisting 
or crying while feeding 
: 3 
2. Mandagni  
Normal, feel hungry within 4 hrs. of food : 0 
intake 
Feel hungry after > 4 to 6 hrs. of food 
intake 
: 1 
Feel hungry after > 6 to 8 hrs. of food 
intake 
: 2 
Does not feel hungry even after 12 hrs. of 
food intake 
: 3 
3. Angamarda (Body ache) 
No body ache : 0 
Body ache after moderate work but 
relieved by rest 
: 1 
Body ache after mild work but relieved 
by res 
: 2 
Continuous body ache does not relieved 
by rest 
: 3 
4. Balakshaya (Fatigueness)  
Normal active child : 0 
Playing and activities are reduced : 1 
Feeling of tiredness while playing : 2 
Easy fatigability while playing : 3 
5. Sandhi Shoola (Joint pain)  
No joint pain : 0 
Pain involve only one extremity : 1 
Pain involve both the extremity : 2 
Involvement of almost all the joints of 
body 
: 3 
6. Udarshoola (Abdominal pain)  
No abdominal pain : 0 
Mild cramping pain only before blood 
transfusion 
: 1 
Moderate cramping pain before 
transfusion and lasting for few days after 
transfusion 
: 2 
Continuous abdominal pain with Irritable 
bowel syndrome 
: 3 
7. Dyspnoea 
No sign of Dyspnoea : 0 
Slight Dyspnoea after heavy work 
relieved by rest 
: 1 
Dyspnoea on slight exertion like walking : 2 
Dyspnoea even at rest : 3 
8. Panduta (Pallor)  
No pallor : 0 
Pallor with shallow pink : 1 
Pallor with slight yellowish tint : 2 
Pallor with ash yellowish tint : 3 
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9. Pleehavriddhi (splenomegaly)  
Non palpable spleen : 0 
Mild splenomegaly (palpable up to 2 cm 
with mild tenderness) 
: 1 
Moderate splenomegaly (palpable up to 4 
cm and tender) 
: 2 
Massive splenomegaly (palpable > 4 cm 
and tender) 
: 3 
10. Yakritvriddhi (Hepatomegaly) 
Non palpable Liver : 0 
Mild Hepatomegaly (palpable up to 2 cm 
with mild tenderness) 
: 1 
Moderate Hepatomegaly (palpable up to 
4 cm and tender) 
: 2 
Massive Hepatomegaly (palpable > 4 cm 
and tender) 
: 3 
11. Irritable bowel syndrome 
Stool with normal frequency and 
consistency 
: 0 
2 to 3 normal motion / day with feeling of 
incomplete evacuation 
: 1 
3 to 4 normal motion / day with feeling of 
incomplete evacuation 
: 2 
> 4 per day which is unformed and 
watery 
: 3 
12. Recurrent respiratory tract infection 
At interval one week or below : 0 
At interval between 7 to 15 days : 1 
At interval between 15 to 45 days : 2 
At interval > 45 days : 3 
RESULTS 
Table 2: Wilcoxon matched paired single ranked test 
(HS: Highly Significant S: Significant NS: Non Significant) 
 
Variable Group Mean Mean 
Diff. 
% 
Relief 
SD± SE± p S 
BT AT 
Arochaka Gr. A 1.15 1.2 0.95 82 0.82 0.18 0.0001 HS 
Gr. B 1.25 1.15 0.10 8 0.30 0.06 0.5 NS 
Mandagni Gr. A 1.85 0.50 1.35 72.97 0.48 0.10 0.0001 HS 
Gr. B 1.75 1.60 0.15 8.57 0.36 0.08 0.25 NS 
Angamard Gr. A 1.7 0.5 1.2 70.58 0.41 0.09 0.0001 HS 
Gr. B 1.7 1.5 0.2 11.76 0.52 0.11 0.25 NS 
Fatigue Gr. A 2.25 0.9 1.35 60 0.67 0.15 0.0001 HS 
Gr. B 2.2 2 0.2 9.09 0.52 0.11 0.1563 NS 
Joint Pain Gr. A 1.75 0.65 1.1 62.8 0.64 0.14 0.0001 HS 
Gr. B 2 1.9 0.1 5 0.44 0.1 0.9999 NS 
Abdominal Pain Gr. A 1.55 0.4 1.15 74.19 0.67 0.15 0.0001 HS 
Gr. B 1.35 1.1 0.25 18.51 0.55 0.12 0.1250 NS 
Dyspnoea Gr. A 1.2 0.5 0.7 58.33 0.57 0.12 0.0002 HS 
Gr. B 1.25 1.15 0.1 8 0.30 0.06 0.500 NS 
Pallor Gr. A 2.1 1.1 1 47.61 0.64 0.14 0.0001 HS 
Gr. B 2.15 1.9 0.25 11.62 0.44 0.09 0.0625 NS 
Splenomegaly Gr. A 1.25 0.95 0.3 24 0.47 0.10 0.0313 S 
Gr. B 0.85 0.8 0.05 5.88 0.22 0.05 0.9999 NS 
Hepatomegaly Gr. A 0.85 0.6 0.25 29.41 0.44 0.09 0.0625 NS 
Gr. B 0.8 0.8 0 0 0.32 0.07 0.9999 NS 
IBS Gr. A 0.85 0.15 0.7 82.35 0.65 0.14 0.0005 HS 
Gr. B 0.9 0.8 0.1 11.11 0.30 0.06 0.500 NS 
Recurrent URTI Gr. A 1.35 1.55 0.8 59.25 0.41 0.09 0.0001 HS 
Gr. B 1.7 1.5 0.2 11.76 0.52 0.11 0.2500 NS 
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Table 3: Intergroup Comparison Mann-Whitney Test 
Effect of Drug on Laboratory Parameters 
Hematological Investigations 
Patients were advised to go for lab investigation before & after Treatment. Data collected was analyzed & 
students Paired t Test was applied.  
Table 4: Hematological Investigations 
Variable Group Mean 
 BT 
Mean 
 AT 
Mean 
 Diff 
% imp SD± SE± t P S 
Hb% A 7.34 7.375 0.03 0.4 1.78 0.39 0.07 0.10 NS 
B 6.79 6.95 0.15 2.28 1.51 0.33 0.458 0.10 NS 
TRBC A 2.66 2.85 0.18 6.83 1.04 0.23 0.78 0.10 NS 
B 2.47 2.53 0.065 2.63 0.51 0.11 0.563 0.10 NS 
TLC A 8.88 9.87 0.98 11.12 3.63 0.81 1.21 0.10 NS 
B 5.79 6.14 0.352 6.07 2.23 0.50 0.70 0.10 NS 
N A 45.66 46.32 0.66 1.44 9.62 2.15 0.30 0.10 NS 
B 46.99 49.08 2.09 4.45 13.86 3.10 0.67 0.10 NS 
L A 46.97 48.75 1.78 3.80 14.16 3.16 0.56 0.10 NS 
B 49.02 47.64 1.38 2.81 11.87 2.65 0.51 0.11 NS 
M A 3.81 4.66 0.84 22.14 3.20 0.71 1.17 0.10 NS 
B 3.68 4.42 0.74 20.10 2.48 0.55 1.32 0.10 NS 
E A 0.14 0.085 0.06 41.37 0.22 0.05 1.18 0.10 NS 
B 0.75 0.25 0.5 66.66 1.57 0.35 1.41 0.10 NS 
PLT A 308.9 284.2 24.75 8.011 73.59 16.45 1.504 0.10 NS 
B 201.4 244.4 43.05 21.37 161 36.09 1.19 0.10 NS 
MCV A 84.19 83.46 0.73 0.867 7.33 1.63 0.44 0.10 NS 
VARIABLE Group Mean Diff. SD± SE± P S 
Arochaka A 0.95 0.80 0.18 0.0001 HS 
B 0.10 0.30 0.06 
Mandagni A 1.35 0.48 0.10 <0.0001 HS 
B 0.15 0.36 0.08 
Angamard A 1.2 0.41 0.09 <0.0001 HS 
B 0.2 0.52 0.11 
Fatigue A 1.35 0.67 0.15 <0.0001 HS 
B 0.2 0.52 0.11 
Joint Pain A 1.1 0.64 0.14 <0.0001 HS 
B 0.1 0.44 0.10 
Abdominal Pain A 1.15 0.67 0.15 <0.0001 HS 
B 0.25 0.55 0.12 
Dyspnoea A 0.70 0.57 0.12 0.0004 HS 
B 0.10 0.30 0.06 
Pallor A 1.00 0.64 0.14 0.0003 HS 
B 0.25 0.44 0.09 
Splenomegaly A 0.30 0.47 0.10 0.0420 S 
B 0.05 0.22 0.5 
Hepatomegaly A 0.25 0.44 0.09 0.0541 NS 
B 0.00 0.32 0.07 
IBS A 0.70 0.65 0.14 0.0010 S 
B 0.10 0.30 0.06 
Recurrent URTI A 0.80 0.41 0.09 0.0002 HS 
B 0.20 0.52 0.11 
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B 84.26 84.73 0.465 0.55 6.23 1.39 0.33 O.10 NS 
MCH A 27.46 27.47 0.015 0.054 2.89 0.64 0.023 0.10 NS 
B 27.55 27.16 0.39 1.41 1.72 0.38 1.01 0.10 NS 
MCHC A 32.63 32.41 0.215 0.658 2.30 0.515 0.416 0.10 NS 
B 32.09 32.00 0.085 0.264 1.47 0.33 0.257 0.10 NS 
(HS: Highly Significant S : Significant NS: Non Significant) 
Table 5: Table showing Results in Serum Parameters in both Groups 
Variable Group Mean 
 BT 
Mean 
 AT 
Mean 
 Diff 
% imp SD± SE± t P S 
Sr. Ferritin A 4006 3485 521 13.00 719.2 160.8 3.239 0.001 S 
B 4060 3546 513.7 12.65 803.2 179.6 2.86 0.01 S 
SGPT A 83.3 63.1 20.2 24.25 27.63 6.18 3.268 0.01 S 
B 96.2 87.1 9.1 9.45 17.69 3.95 2.29 0.05 NS 
Sr. Urea A 29.2 23.3 5.9 20.20 7.77 1.73 3.39 0.01 S 
B 30.35 26.4 3.95 13.01 6.54 1.46 2.70 0.02 NS 
Sr. Creatinine A 0.763 0.693 0.070 9.23 0.100 0.022 3.130 0.01 S 
B 0.774 0.747 0.027 3.55 0.149 0.033 0.825 0.10 NS 
(HS: Highly Significant S: Significant NS: Non Significant) 
 Effect on Arochaka, Mandagni, Angamard, 
Fatigue, Joint Pain, Abdominal Pain, 
Dyspnoea, Pallor, IBS, Recurrent URTI in 
Group A was statistically highly significant. 
In Group B showed statistically non 
significant results.  
 Effect on splenomegaly: In Group the 
effect was statistically significant. In Group 
B statistically non significant.  
 Effect on Hepatomegaly: In Group A and 
Group B the effect was statistically non 
significant. 
DISCUSSION 
Intergroup Comparison by Mann-Whitney Test 
The present clinical trial is a comparative 
clinical study. So to access comparison between 
the efficacies of two therapies intergroup 
comparison was done. As the variables are 
nonparametric we used Mann-Whitney Test for 
statistical analysis & the obtained results are as 
follows. 
The intergroup comparison showed that 
there is statistically highly significant difference in 
efficacy of both treatments on Arochaka, 
Mandagni, Angamard, Fatigue, Joint Pain, 
Abdominal Pain, Dyspnoea, Pallor and Recurrent 
URTI. It also showed that there is significant 
difference in efficacy of both treatments on 
splenomegaly and IBS. There is no statistical 
significant difference in efficacy of both 
treatments on hepatomegaly. 
 
Effect of Drug on Laboratory Parameters 
Hematological Investigations: Patients were 
advised to go for lab investigation before & after 
Treatment. Data collected was analyzed & 
students Paired t Test was applied. This showed 
that No significant change was observed on any 
haematological parameters. 
Results in Serum Parameters in both Groups 
Sr. Ferritin: Group A Mean Sr. Ferritin before 
treatment was changed from 4006 to 3485 having 
13% improvement which is statistically 
significant. Group B Mean Sr. Ferritin before 
treatment was changed from 4060 to 3546 having 
12.65% improvement which is statistically 
significant.  
SGPT: Group A Mean SGPT before treatment was 
changed from 83.3 to 63.1 having 24.25% 
improvement which is statistically significant. 
Group B Mean SGPT before treatment was 
changed from 96.2 to 87.1 having 9.45% 
improvement which is statistically non-
significant. 
Sr. Urea: Group A Mean SGPT before treatment 
was changed from 29.2 to 23.3 having 20.20% 
improvement which is statistically significant. 
Group B Mean SGPT before treatment was 
changed from 30.35 to 26.4 having 13.01% 
improvement which is statistically non-
significant. 
Sr. Creatinine: Group A Mean Sr. Creatinine 
before treatment was changed from 0.76 to 0.69 
having 9.23% improvement which is statistically 
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significant. Group B Mean Sr. Creatinine before 
treatment was changed from 0.77 to 0.74 having 
3.55% improvement which is statistically non-
significant. 
Probable Mode of action 
According to Ayurveda 
This condition is caused by vitiation of 
Tridosha. The drugs Haritaki, Aamalaki are 
Tridoshashamaka, Bibhitakikaphahara, Shunthi, 
Marich, Pippali, Vidanga are Kapha, Vatashamaka, 
Musta and Agasti are Kapha pitta shamaka, 
Kushmanada Vatapittahara and Yavakshara 
Kaphahara. In this condition the Angimandya is 
also there, so Dipan is the Chikitsa. Amalaki, 
Haritaki, Marich, Vidanaga are Agnidipan 
Dravyas.(15) Vidanga and Agasti are helpful in 
reducing the Lohadosh by Prabhava.(7),(16) 
According to modern science 
 Polyphenolic compounds, tannins present in 
the herbal drugs and element calcium are 
supposed to inhibit the absorption of iron. 
 Polyphenolic compounds reportedly have a 
wide range of effects in vivo and in vitro, 
including antioxidant and metal-chelating 
activities (17). 
 They promote the healing of tissues and 
prevent free-radical oxidative damage. 
 In present drug Haritaki(18), Bibhitaki(19) and 
Vidanga(20) contain tannins and thereby 
reducing the absorption of iron. 
 It is reported that Embelline in Vidanga 
showed iron chelating activity in some of the 
Lauha preparations like Vidangadi Lauha, 
Saptamrit Lauha etc.(21) 
 Apart from tannins the Haritaki(22) contains 
polyphenolic compounds which also help in 
inhibition of iron absorption from the food. 
 Kushmanda contains calcium. It acts as 
competitive antagonist to iron and therefore 
it also minimizes the absorption. 
 The contents like Pippali and Maricha contain 
piperine as one of the constituent make the 
drugs like Haritaki, Bibhitaki, Aamalaki and 
Kushmanda biologically more available. The 
piperine may also help to improve the 
bioavailability of the modern iron 
chelators.(23) 
 Antioxidants and essential nutrients enhance 
the chelation process by replacing the small 
losses of beneficial minerals that are removed 
during chelation. They promote the healing of 
tissues and prevent free-radical oxidative 
damage. As with the chelating agents, the 
antioxidants in test drugs help neutralize free 
radicals that are formed by a variety of 
oxidizing agents.  
CONCLUSION 
1. This preparation did not impart any side 
effect; Lohadosh Niwaraka Yog at the given 
dose was well tolerated by the patient 
without any undesirable side effect of 
Nausea, Vomiting etc. 
2. In the experimental group the serum ferritin 
levels are reduced and no any adverse drug 
reactions were seen suggesting that the drug 
has not caused any drug interaction or have 
not interfered with the action of Kelfer.  
3. From the results obtained it is concluded that 
the Lohadosh Niwaraka Yog used as a 
supportive treatment so that the general 
health of the patient should be maintained. 
4. Splenomegaly is seen in many patients of 
Thalassaemia, as this drug has helped to 
reduce the spleen size it has to be 
recommended for this purpose in the regular 
treatment. 
5. The associated symptoms like Agnimandya, 
Arochak, and recurrent URTI etc. are well 
managed with this treatment. 
6. This type of integrated approach is helpful in 
treating diseases like Thalassaemia. 
7. The lowering of SGPT implies that the drug 
has good action on liver. Also the serum urea, 
creatinine values are also reduced which 
shows that this trial drug has action on 
kidney function also. 
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